Italia markets close in 8 hours 30 minutes

Onward Medical N.V. (ONWD.BR)

Brussels - Brussels Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
4,8700+0,1200 (+2,53%)
In data: 05:35PM CEST. Mercato aperto.
Schermo intero
Chiusura precedente4,7500
Aperto4,8400
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno4,7600 - 4,8900
Intervallo di 52 settimane1,8500 - 6,5800
Volume31.727
Media Volume136.345
Capitalizzazione168,642M
Beta (5 anni mensile)0,81
Rapporto PE (ttm)N/D
EPS (ttm)-1,2000
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A13,90
  • GlobeNewswire

    ONWARD Schedules Webcast to Provide Third Quarter 2023 Business Update

    Eindhoven, Netherlands, Oct. 11, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury, today announced that it will host a webcast to discuss its Q3 2023 business highlights. The webcast will be held on November 16, 2023, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver and CFO Khaled Bahi, who will discuss highlights from Q3 202

  • GlobeNewswire

    ONWARD® Announces First-in-Human Implant of ARC-IM™ Stimulator with Brain-Computer Interface (BCI) to Restore Arm, Hand, and Finger Function after Spinal Cord Injury

    Pioneering procedure pairs Company’s investigational ARC-IM implantable spinal cord stimulator with an investigational brain-computer interfaceEindhoven, Sept. 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces the successful first-in-human implant of its ARC-IM Stimulator*, to restore upper e

  • GlobeNewswire

    ONWARD® Reports 2023 Half Year Results and Business Update

    Eindhoven, Sept. 19, 2023 (GLOBE NEWSWIRE) -- THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) US commercialization of ARC-EX™ expected 2H 2024 with USD 30,000 anticipated price Clinical study initiated pairing ARC Therapy™ with a brain-computer interface to restore use of legs and upper extremities ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movem